Equities analysts expect that Synlogic (NASDAQ:SYBX) will announce earnings per share (EPS) of ($0.75) for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Synlogic’s earnings, with estimates ranging from ($1.02) to ($0.62). Synlogic posted earnings of ($0.84) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 10.7%. The firm is expected to report its next earnings report on Tuesday, May 8th.
According to Zacks, analysts expect that Synlogic will report full year earnings of ($2.98) per share for the current fiscal year, with EPS estimates ranging from ($3.88) to ($2.35). For the next year, analysts anticipate that the firm will post earnings of ($3.09) per share, with EPS estimates ranging from ($3.96) to ($2.34). Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Synlogic.
Synlogic (NASDAQ:SYBX) last posted its quarterly earnings results on Tuesday, March 20th. The biotechnology company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.07. The business had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.11 million.
SYBX has been the topic of several research reports. HC Wainwright initiated coverage on shares of Synlogic in a research note on Monday, March 19th. They set a “buy” rating and a $20.00 price target on the stock. Piper Jaffray reissued a “buy” rating and set a $15.00 price target on shares of Synlogic in a research note on Monday, April 9th. ValuEngine downgraded shares of Synlogic from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Finally, Zacks Investment Research downgraded shares of Synlogic from a “hold” rating to a “sell” rating in a research note on Wednesday, January 31st. Two analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $20.00.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Spark Investment Management LLC purchased a new position in shares of Synlogic in the fourth quarter worth $105,000. Deutsche Bank AG increased its stake in shares of Synlogic by 204.0% in the fourth quarter. Deutsche Bank AG now owns 19,672 shares of the biotechnology company’s stock worth $190,000 after buying an additional 13,200 shares during the period. Renaissance Technologies LLC purchased a new position in shares of Synlogic in the fourth quarter worth $191,000. Finally, Artal Group S.A. purchased a new position in shares of Synlogic in the fourth quarter worth $5,335,000. 48.97% of the stock is currently owned by institutional investors.
SYBX stock opened at $11.46 on Thursday. The company has a market cap of $229.55, a price-to-earnings ratio of -1.95 and a beta of 2.22. Synlogic has a one year low of $8.76 and a one year high of $23.00. The company has a current ratio of 9.82, a quick ratio of 9.82 and a debt-to-equity ratio of 0.01.
WARNING: This story was first posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.thelincolnianonline.com/2018/04/22/synlogic-sybx-expected-to-announce-earnings-of-0-75-per-share.html.
Synlogic, Inc develops synthetic biotic medicines for the treatment of patients with urea cycle disorder and phenylketonuria. The company is based in Cambridge, Massachusetts.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.